NORINYL 1+35–28 Rx
Generic Name and Formulations:
Norethindrone 1mg, ethinyl estradiol 35micrograms (21 tabs); inert (7 tabs).
Indications for NORINYL 1+35–28:
1 tab daily for 28 days, repeat.
Premenarchal: not applicable.
Thrombophlebitis or thromboembolic disorders. Cerebral vascular or coronary artery disease. Breast or other estrogen-dependent neoplasms. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior OC use. Hepatic disease or tumors. Pregnancy (Cat.X). Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.
Cigarette smoking increases risk of serious cardiovascular events.
Increased risk of cardiovascular events esp. in cigarette smokers >35yrs of age. Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism, and during and after prolonged immobilization. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Hypertriglyceridemia. Gallbladder disease. History of depression; monitor and discontinue if serious depression recurs. Fluid retention. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Do regular complete physical exams. Monitor BP; discontinue if significant rise occurs. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Nursing mothers: not recommended.
Progestin + estrogen.
See Contraindications. ALT elevations with HCV regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; discontinue Norinyl prior to starting HCV regimen and restart 2wks after completion. May be antagonized by hepatic enzyme inducers (eg, rifampin, barbiturates, phenylbutazone, phenytoin, griseofulvin, ampicillin, tetracycline, St. John's wort). May affect lab tests (eg, coagulation factors, thyroid hormones, triglycerides, lipids, glucose tolerance, binding proteins, hormone binding globulins, serum folate).
Nausea, vomiting, breakthrough bleeding, amenorrhea, transient delay of ovulation after discontinuation, edema, melasma, headache, intolerance to contact lenses; hypertension, serious thromboembolic events, liver disease.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Characteristics of Unipolar Mania, Distinct from Bipolar Disorder, Described
- Aspirin, N-Acetylcysteine Effective Adjunctive Treatments in Bipolar Depression
- Subthreshold Pediatric Bipolar Disorder Is a Significant Psychiatric Burden
- Interview-Only Version of Yale-Brown Obsessive-Compulsive Scale Effective for OCD Monitoring in Youth
- Potential Biomarker Differentiates Between Bipolar Disorder With, Without Psychosis
- Part 1: Adolescent Tech Use and Mental Health: Expert Roundtable
- Challenging Stigma: Should Psychiatrists Disclose Their Own Mental Illness?
- Social Anxiety in Schizophrenia: An Overlooked Problem
- Inflammation: Is It the Link Between Rheumatoid Arthritis and Depression?
- Childhood Physical Violence Associated With Decreased Total Cholesterol
- How the Government Shutdown Affects FDA Activities
- The Robot Will See You Now: The Increasing Role of Robotics in Psychiatric Care
- Extended-Release Naltrexone Improves Psychiatric Disorders During Addiction Therapy
- Infections, Antibiotics Associated With Subsequent Increased Risk for Mental Disorders in Youth